PDCD1 and neoplasm: Third, correlative studies of biomarkers driven by STAT3 activity, signaling pathway abnormalities, and/or immunotherapy (e.g., PD-1/ PD-L1 expression on the tumor or tumor-infiltrating cells) were not performed.